A new epigenetic methodology makes it possible to reconstruct the evolution of cancer and anticipate its clinical progression

by Fundació Clínic per a la Recerca Biomèdica

The research team discovered that the original cell that gave rise to the tumour leaves a unique methylation signature, a fingerprint that not only reveals the identity of the tumour cells, but also c...

Read more

Epigenetics Key to Understanding Stroke Risk and Recovery

by Hospital de la Santa Creu i Sant Pau

The review highlights that DNA methylation appears to be a relevant mechanism in stroke. Several studies have identified specific methylation patterns associated with a higher risk of experiencing a c...

Read more

ORYZON at ASH-2021: iadademstat 36-month ALICE data demonstrate robust efficacy in combination with azacitidine in AML

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents ...

Read more

ORYZON announces new Global Chief Business Officer and expansion of US corporate activities

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

Read more

ORYZON to present new clinical data and corporate updates at international conferences in June and July

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

ORYZON receives the INNOVATIVE SME seal from the Ministry of Science and Innovation

by Oryzon Genomics

Innovation present in Oryzon's programs in the field of epigenetics acknowledged Oryzon currently has 2 compounds in Phase II clinical studies, iadademstat and vafidemstat

Read more

ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Acute Myeloid Leukemia

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today an...

Read more

ORYZON to present new clinical data and corporate updates at conferences in February and March

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

Read more

ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

Read more

ORYZON to present further positive efficacy data from iadademstat ALICE Phase IIa trial at the 62nd Congress of the American Society of Hematology

by Oryzon Genomics

ORYZON to present further positive efficacy data from iadademstat ALICE Phase IIa trial at the 62nd Congress of the American Society of Hematology

Read more

ORYZON receives approval to start PORTICO Phase IIb trial with vafidemstat in Borderline Personality Disorder

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

Oryzon announces appointment of Dr. Torsten Hoffmann as Global R&D Director and retirement of Dr. Tamara Maes

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New breakthrough in developing more pers...

by Universitat de Barcelona

The results show that adenocarcinoma exhibits much more active and fun...

Photos Stream